{
  "docId": "019de074-a4f4-74e1-8870-171c8951fea8",
  "docSlug": "e0247ed9fbf6e59fd6aeeea6f3eacc2d",
  "documentTitle": "23andMe | Investor Presentation Deck | 57 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 57,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "roadmap",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a gradient bar chart to represent the progression of drug development programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a4f4-74e1-8870-171c8951fea8/35",
  "deckHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8",
  "deckJsonHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8.json",
  "deckAnchorHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.31,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Pipeline progression bars for GSK'608 and 23ME'610",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85d695b3-08b6-403f-95ff-6ab1476ae45b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. GSK is solely responsible for the development of GSK6097608 (GSK'608) in later-stage clinical trials. Subject to its successful commercialization, 23andMe is eligible to earn tiered worldwide royalties up to the low double digits.\n2. The 50+ programs in the combined therapeutic areas include 100% owned and royalty interest targets as well as those in collaborations. The majority of the programs are in collaboration with GSK. Note: As of March 31, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85d0f1d1-60b8-420e-83b9-8b6bcb9c3c8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.5,
        "y": 0.53
      },
      "kind": "metric",
      "text": "50+ programs",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a4d23ee-8b77-4937-906b-8852a4b8bec9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.76,
        "x": 0.12,
        "y": 0.05
      },
      "kind": "title",
      "text": "A Research and Development Pipeline Covering Multiple Therapeutic Areas",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1764aed-605b-4656-8e6f-8d4b0deb71c7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "06397854-2375-4f1c-a310-d6a629829e9c",
      "evidence": "Pipeline progression visualization",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}